Handelsavisen
prelaunch
Companies Healthcare DYAI.O
DY
DYAI.O NASDAQ Biotechnology & Life-Science Tools

Dyadic International Inc

$1,03
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
37,5M USD
P/E
EV / Rev
Div yield
Op margin
-232,8 %
ROE
-597,6 %
Net margin
-238,3 %
Debt / equity
4,08
Beta
52w range
Volume
264
Day range
$0,73–$0,77
Prev close
$0,76
Open
$0,74
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

Dyadic International Inc is a biotechnology company focused on the development and commercialization of diagnostic and therapeutic products for the healthcare industry.

Business. Dyadic International Inc (DYAI.O) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification99 %
SectorHealth Care
Industry groupBiotechnology & Life-Science Tools
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target6,00

Analyst recommendations

1 analysts · consensus Buy
Buy1
Hold0
Sell0
12-month price target
6,00
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
1 analysts · indicative
Ownership
Geode Capital Management, L.L.C.
largest disclosed fund holder
Profitability
-597,6 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning DYAI.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to DYAI.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    Briefing · model-assisted

    Dyadic International Inc (DYAI.O) has entered the scope of analysis, marking the first available data point for the ticker with no prior basis for delta computation. This initial coverage reveals a notable shift in shareholder composition, characterized by multiple new institutional holdings detected across recent reporting periods. The most significant addition involves an investor (ID 465) who held 914,960 shares valued at approximately $0.86 million as of December 31, 2025. This position represents a weight of roughly 0.0012% of the company's equity, signaling a substantial entry relative to other recent additions. Additional notable additions were recorded as of March 31, 2026, including an investor (ID 467) holding 42,550 shares valued at $0.035 million and another (ID 517) holding 33,038 shares valued at $0.027 million. Smaller positions were also added by investors with IDs 486, 502, and 510, with share counts ranging from 178 to 32,851. These changes occur within a company profile that currently lists one officer and nine top holders, with no analyst coverage or index membership recorded. The accumulation of these new positions suggests growing institutional interest, providing a baseline for future monitoring of ownership trends and potential market impact.

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Dyadic International Inc (DYAI.O) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification99 %
    SectorHealth Care
    Industry groupBiotechnology & Life-Science Tools
    AI synthesis
    GENERATED

    Dyadic International Inc has a market capitalization of $28.6 million and a price-to-book ratio of 23.2, indicating a high valuation relative to its book value. The company's liquidity position is characterized by $4.6 million in cash and equivalents, but it also carries $5.0 million in long-term debt, resulting in a debt-to-equity ratio of 4.08. The current ratio of 2.68 suggests the company has sufficient current assets to cover its current liabilities.

    The company's profitability is weak, with a net loss of $7.4 million and an operating loss of $7.2 million in the latest reporting period. Return on equity is negative at -5.98%, and return on assets is also negative at -0.74%, indicating poor capital efficiency and asset utilization. The company's gross profit of $770,490 is significantly lower than its operating and net losses, highlighting the challenges in converting revenue into profit.

    Dyadic International Inc operates in a single business segment, and its geographic exposure is not disclosed in the available data. The company's revenue concentration is not specified, but the lack of segment or geographic breakdown suggests a relatively undiversified business model.

    The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. The operating cash flow is negative at -$5.7 million, indicating that the company is not generating sufficient cash from operations to sustain its activities. The company's financial performance and cash flow position suggest a need for external financing or operational improvements to achieve sustainable growth.

    The risk assessment for Dyadic International Inc indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could impact its ability to meet short-term obligations. The low dilution risk suggests that the company is not expected to issue a significant number of new shares in the near term, which is a positive sign for existing shareholders.

    Recent events and disclosures for Dyadic International Inc include analyst price targets ranging from $5.00 to $7.00, with a mean and median price target of $6.00. The mean recommendation from analysts is 2.00, indicating a "buy" rating, with one analyst issuing a "buy" recommendation and none issuing a "strong buy" or "hold". These analyst estimates suggest a generally positive outlook, but the lack of strong buy ratings indicates some caution among analysts.

    Dyadic International Inc (DYAI.O) has entered the scope of analysis, marking the first available data point for the ticker with no prior basis for delta computation. This initial coverage reveals a notable shift in shareholder composition, characterized by multiple new institutional holdings detected across recent reporting periods. The most significant addition involves an investor (ID 465) who held 914,960 shares valued at approximately $0.86 million as of December 31, 2025. This position represents a weight of roughly 0.0012% of the company's equity, signaling a substantial entry relative to other recent additions. Additional notable additions were recorded as of March 31, 2026, including an investor (ID 467) holding 42,550 shares valued at $0.035 million and another (ID 517) holding 33,038 shares valued at $0.027 million. Smaller positions were also added by investors with IDs 486, 502, and 510, with share counts ranging from 178 to 32,851. These changes occur within a company profile that currently lists one officer and nine top holders, with no analyst coverage or index membership recorded. The accumulation of these new positions suggests growing institutional interest, providing a baseline for future monitoring of ownership trends and potential market impact.

    Key takeaways
    • Dyadic International Inc has a high price-to-book ratio of 23.2, indicating a premium valuation relative to its book value.
    • The company is currently unprofitable, with a net loss of $7.4 million and an operating loss of $7.2 million.
    • The company's liquidity position is mixed, with $4.6 million in cash and equivalents but a debt-to-equity ratio of 4.08.
    • Analysts have a generally positive outlook, with a mean price target of $6.00 and a "buy" recommendation.
    • The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $1,03
    Market cap
    $28.6M
    Enterprise value
    $29.0M
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    23.2x
    P / Tangible book
    23.2x
    Tangible book
    $1.2M
    Net cash
    -$403.7k
    Current ratio
    2.7
    Debt / equity
    4.1
    ROA
    -74.1%
    ROE
    -6.0%
    Cash conversion
    77.0%
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryBiotechnology & Life-Science Tools27,7B node revenueIQV 58,8%CRL 14,5%MEDP 9,1%ALKS 5,3%PIII 5,3%ORGO 2,0%NAGE 0,5%SPRY 0,3%Other 4,2%
    Source: company disclosures · own-taxonomy revenue-covered setDYAI 0,0% · rank #48 of 78

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    Peer comparison8 peers · vs DYAI · multiples and returns
    IQ
    IQV
    Iqvia Holdings Inc
    $181,94
    30,9B USD
    P/E
    22,7x
    vs self
    Div yield
    vs self
    ROE
    21,9 %
    +619,4 vs self
    CR
    CRL
    Charles River Laboratories
    $230,87
    11,4B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -4,6 %
    +593,0 vs self
    ME
    MEDP
    Medpace Holdings Inc
    $576,00
    16,7B USD
    P/E
    34,4x
    vs self
    Div yield
    vs self
    ROE
    75,4 %
    +673,0 vs self
    AL
    ALKS
    Alkermes PLC
    $49,53
    8,2B USD
    P/E
    39,8x
    vs self
    Div yield
    vs self
    ROE
    8,4 %
    +606,0 vs self
    PI
    PIII
    P3 Health Partners Inc
    $10,20
    73,8M USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    95,3 %
    +692,9 vs self
    OR
    ORGO
    Organogenesis Holdings Inc
    $2,38
    306,2M USD
    P/E
    9,0x
    vs self
    Div yield
    vs self
    ROE
    8,5 %
    +606,1 vs self
    NA
    NAGE
    Niagen Bioscience Inc
    $3,53
    281,1M USD
    P/E
    17,4x
    vs self
    Div yield
    vs self
    ROE
    22,7 %
    +620,3 vs self
    SP
    SPRY
    Ars Pharmaceuticals Inc
    $5,51
    547,1M USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -149,9 %
    +447,7 vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 33 %
    EPS
    Consensus EPS
    -0,09
    Predicted surprise
    -0,02
    Beat probability
    33 %
    Analysts
    1
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-08 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate-0,09
    Revenueno estimateno estimate6,8M USD
    Operating incomeno estimateno estimate-3,7M USD
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Corporate eventM&A horizon
    M&A probabilityconf 5 %
    Probability
    5 %
    Base rate
    3 %
    Band
    180-day horizon · target 2027-01-16 · 1,8× base rate
    No acquirer candidates identified by the signal model.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy1
    Hold0
    Sell0
    Strong sell0
    12-month price target$6,00 · Median $6,00
    Low $5,00High $7,00
    Operating income · consensus-3,7M USD
    EPS surprise
    −151,1 %
    reported vs consensus · miss
    Revenue surprise
    −54,2 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$5,00
    Mean$6,00
    Median$6,00
    High$7,00
    Spot$1,03
    +482.5 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-232,8 %Above median
    Net Margin-238,3 %Above median
    ROE-597,6 %Bottom quartile
    D/E4,08Bottom quartile
    Cash Conv0,77Below median

    Corporate actions / M&A

    M&A probabilityconf —
    Probability
    5 %
    Base rate
    3 %
    Band
    Moderate
    180-day horizon · target 2027-01-16 · 1,8× base rate
    No acquirer candidates identified by the signal model.
    Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 1 718 252 sh3 exercises · 11 grants8 insiders
    • HERBST SETHDirector · Restricted Stock Unit → Common StockAcquired 39 894grant · 2026-01-02
    • TCHELET RONENVP of Research and Bus. Dvlpmt · Stock Option → Common StockAcquired 47 250 @ $0,94grant · 2026-01-02
    • Rawson Ping WangChief Financial Officer · Stock Option → Common StockAcquired 47 250 @ $0,94grant · 2026-01-02
    • Lucy Patrick K.Director · Restricted Stock Unit → Common StockDisposed 21 552exercise · 2026-01-02
    • Lucy Patrick K.Director · Stock Option → Common StockAcquired 67 500 @ $0,94grant · 2026-01-02
    • Lucy Patrick K.Director · Restricted Stock Unit → Common StockAcquired 39 894grant · 2026-01-02
    • Kaye JackDirector · Restricted Stock Unit → Common StockDisposed 21 552exercise · 2026-01-02
    • Kaye JackDirector · Stock Option → Common StockAcquired 67 500 @ $0,94grant · 2026-01-02
    • Kaye JackDirector · Restricted Stock Unit → Common StockAcquired 39 894grant · 2026-01-02
    • HERBST SETHDirector · Restricted Stock Unit → Common StockDisposed 21 552exercise · 2026-01-02
    • HERBST SETHDirector · Stock Option → Common StockAcquired 50 000 @ $0,94grant · 2026-01-02
    • Hazelton Joseph PPresident & COO · Stock Option → Common StockAcquired 67 250 @ $0,94grant · 2026-01-02
    • EMALFARB MARK ADirector, CEO, 10% owner · Stock Option → Common StockAcquired 126 000 @ $0,94grant · 2026-01-02
    • Francisco Trust under agreement dated February 28, 199610% owner · Common Stock → Common StockAcquired 238 095 @ $1,05other · 2025-12-23
    • EMALFARB MARK ADirector, CEO, 10% owner · Senior Secured Convertible Promissory Note due Dec 31, 2027 → Common StockAcquired 952 381 @ $1,05grant · 2025-12-23
    • EMALFARB MARK ADirector, CEO, 10% owner · Senior Secured Convertible Promissory Note due March 8, 2027 → Common StockDisposed 714 286 @ $1,40disposition · 2025-12-23
    • EMALFARB MARK ADirector, CEO, 10% owner · Senior Secured Convertible Promissory Note due March 8, 2027 → Common StockAcquired 714 286 @ $1,40purchase · 2025-09-15

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    Source documents
    • Dyadic International Inc Market data — financials · 2026-05-27
    • Dyadic International Inc Market data — analyst estimates · 2026-05-27

    Ownership & reference

    Top holders

    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$0M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$1M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$0M
    • LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$0M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M

    Leadership

    • Mark A. EmalfarbPresident, Chief Executive Officer, Director

    Insider activity

    Net selling0 buys · 3 sellsnet -$125K8 insiders · last 365d
    • Francisco Trust under agreement dated February 28, 199610% owner · Common StockSold 2 616 @ $1,21$3K · 2026-07-24
    • Francisco Trust under agreement dated February 28, 199610% owner · Common StockSold 54 760 @ $1,30$71K · 2026-07-23
    • Francisco Trust under agreement dated February 28, 199610% owner · Common StockSold 38 016 @ $1,33$50K · 2026-07-22
    • EMALFARB MARK ADirector, CEO, 10% owner · Common StockOther 102 609 · 2026-01-02
    • Lucy Patrick K.Director · Common StockOther 21 552 · 2026-01-02
    • Kaye JackDirector · Common StockOther 21 552 · 2026-01-02
    • HERBST SETHDirector · Common StockOther 21 552 · 2026-01-02
    • Hazelton Joseph PPresident & COO · Common StockOther 36 418 · 2026-01-02
    • TCHELET RONENVP of Research and Bus. Dvlpmt · Common StockOther 18 064 · 2026-01-02
    • Rawson Ping WangChief Financial Officer · Common StockOther 29 158 · 2026-01-02

    Short positioning

    83.5Kshares short-52.2% vs prior
    1days to cover
    48.0%short of daily vol
    1.2Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    DYAI.OCanonical
    NASDAQ · USD

    Intel & risk

    PredictorBeat prob33 %Surprise-0,02M&A prob5 %Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    • Revenue (YoY) (2025-12-31 vs 2024-12-31): -11.6%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): 0.2%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -15.0%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -29.0%Derived (calculated)
    • Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 94.2%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): -26.8%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -43.5%Derived (calculated)
    • Current ratio (FY 2025-12-31): 2.68xDerived (calculated)
    • Return on assets (FY 2025-12-31): -74.0%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -50.1%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): -21.9%Derived (calculated)
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): 5.4%Derived (calculated)
    • Debt-to-equity (FY 2025-12-31): 7.07xDerived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 16.8%Derived (calculated)
    • Net margin (FY 2025-12-31): -238.3%Derived (calculated)
    • Return on equity (FY 2025-12-31): -597.6%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -15.0%Derived (calculated)
    • EPS (basic) (annual): USD-PER-SHARES -0SEC XBRL filing
    • Operating income (annual): USD -7.19MSEC XBRL filing
    • R&D expense (annual): USD 2.15MSEC XBRL filing
    • EPS (diluted) (annual): USD-PER-SHARES -0SEC XBRL filing
    • Operating cash flow (annual): USD -5.7MSEC XBRL filing
    • Total liabilities (annual): USD 8.71MSEC XBRL filing
    • Cash & equivalents (annual): USD 4.62MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-07-29 22:34 UTCEVENTHa Price Listing DYAI remains DEFICIENT (NASDAQ) — cure period. closed below $1.00 for 119 consecutive trading days (last close $0.682). cure deadline 2027-01-17 (172 days remaining).
    2026-07-24INSIDERFrancisco Trust under agreement dated February 28, 1996 sold 2.6k sh — 10% owner ~$3k
    2026-07-23INSIDERFrancisco Trust under agreement dated February 28, 1996 sold 54.8k sh — 10% owner ~$71k
    2026-07-22INSIDERFrancisco Trust under agreement dated February 28, 1996 sold 38.0k sh — 10% owner ~$50k
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)
    2026-06-21 02:57 UTCHOLDERInstitutional holding changed
    2026-06-21 02:57 UTCHOLDERInstitutional holding changed
    2026-06-21 02:57 UTCHOLDERInstitutional holding changed
    2026-06-21 02:57 UTCHOLDERInstitutional holding changed
    2026-06-21 02:57 UTCHOLDERInstitutional holding changed
    2026-06-21 02:57 UTCHOLDERInstitutional holding changed
    2026-06-21 02:57 UTCHOLDERInstitutional holding changed
    2026-06-21 02:57 UTCHOLDERInstitutional holding changed
    2026-06-21 02:57 UTCHOLDER8 institutional position changes flagged
    2026-06-18FILING8-K filing →
    2026-06-15FILING8-K filing →
    2026-05-28FILING8-K filing →
    2026-05-13FILING8-K filing →
    2026-05-13FILING10-Q filing →
    2026-05-12FILINGDEF 14A filing →
    2026-03-30FILING8-K filing →
    2026-03-25FILING8-K filing →
    2026-03-25FILING10-K filing →
    2026-03-06FILING8-K filing →
    2026-03-06FILING424B5 filing →
    2026-01-02 00:00 UTCINSIDER20 insider transactions — 2026-01 13 derivative
    2026-01-02 00:00 UTCINSIDER20 insider transactions — 2026-01 13 derivative
    2026-01-02INSIDEREMALFARB MARK A transacted 102.6k sh — Director, CEO, 10% owner
    2026-01-02INSIDERLucy Patrick K. transacted 21.6k sh — Director
    2026-01-02INSIDERKaye Jack transacted 21.6k sh — Director
    2026-01-02INSIDERHERBST SETH transacted 21.6k sh — Director
    2026-01-02INSIDERHazelton Joseph P transacted 36.4k sh — President & COO
    2026-01-02INSIDERTCHELET RONEN transacted 18.1k sh — VP of Research and Bus. Dvlpmt
    2026-01-02INSIDERRawson Ping Wang transacted 29.2k sh — Chief Financial Officer
    2026-01-02INSIDERKaye Jack disposed of 21.6k sh Restricted Stock Unit — Director
    2026-01-02INSIDEREMALFARB MARK A acquired 126.0k sh Stock Option — Director, CEO, 10% owner
    2026-01-02INSIDERHazelton Joseph P acquired 67.2k sh Stock Option — President & COO
    2026-01-02INSIDERHERBST SETH acquired 39.9k sh Restricted Stock Unit — Director
    Showing the 40 most recent of 60 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage